Symbols / HURA $2.14 +1.90%
HURA Chart
About
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-specific antibody-peptide conjugates and antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 120.86M |
| Enterprise Value | 105.93M | Income | -29.29M | Sales | — |
| Book/sh | 0.32 | Cash/sh | 0.05 | Dividend Yield | — |
| Payout | 0.00% | Employees | 19 | IPO | — |
| P/E | — | Forward P/E | -4.17 | PEG | — |
| P/S | — | P/B | 6.65 | P/C | — |
| EV/EBITDA | -4.18 | EV/Sales | — | Quick Ratio | 0.35 |
| Current Ratio | 0.40 | Debt/Eq | 4.21 | LT Debt/Eq | — |
| EPS (ttm) | -0.74 | EPS next Y | -0.51 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-26 | ROA | -60.16% |
| ROE | -4.18% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 56.48M |
| Shs Float | 32.40M | Short Float | 15.10% | Short Ratio | 2.02 |
| Short Interest | — | 52W High | 4.44 | 52W Low | 0.41 |
| Beta | — | Avg Volume | 1.66M | Volume | 6.76K |
| Target Price | $8.62 | Recom | Strong_buy | Prev Close | $2.10 |
| Price | $2.14 | Change | 1.90% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.63
Mean price target
2. Current target
$2.11
Latest analyst target
3. DCF / Fair value
$-0.46
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.11
Low
$7.50
High
$10.00
Mean
$8.63
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-03 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-11-14 | main | Maxim Group | Buy → Buy | $8 |
| 2025-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-04-03 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-03-03 | init | HC Wainwright & Co. | — → Buy | $13 |
| 2024-12-19 | init | Rodman & Renshaw | — → Buy | $11 |
- TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering - PR Newswire ue, 09 Dec 2025 08
- (HURA) Risk-Controlled Trading Report (HURA:CA) - Stock Traders Daily Sat, 14 Mar 2026 16
- Wall Street Zen Upgrades TuHURA Biosciences (NASDAQ:HURA) to "Hold" - MarketBeat Sat, 14 Mar 2026 06
- HURA Stock Price and Chart — NASDAQ:HURA - TradingView hu, 16 Oct 2025 07
- Cancer immunotherapy firm TuHURA keeps share price over $1 to satisfy Nasdaq - Stock Titan Fri, 27 Feb 2026 08
- The recent pullback must have dismayed TuHURA Biosciences, Inc. (NASDAQ:HURA) insiders who own 43% of the company - simplywall.st hu, 23 Oct 2025 07
- HURA Stock Sparks 7,000% Surge In Retail Chatter After FDA Orphan Drug Win For Melanoma Therapy - Stocktwits ue, 03 Feb 2026 07
- TuHURA Biosciences, Inc.'s (NASDAQ:HURA) last week's 11% decline must have disappointed retail investors who have a significant stake - Yahoo Finance Mon, 11 Aug 2025 07
- TuHURA Biosciences stock gains after Nasdaq compliance - Investing.com Fri, 27 Feb 2026 08
- TuHURA Biosciences (NASDAQ:HURA) Trading Down 3.1% - Here's Why - MarketBeat Sat, 14 Mar 2026 06
- TuHURA Biosciences: Potential In Immunotherapy Resistance, But How Will It Be Funded? - Seeking Alpha Mon, 17 Nov 2025 08
- TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement - PR Newswire Fri, 27 Feb 2026 08
- TuHURA Biosciences (NASDAQ: HURA) outlines 2026 trial milestones after $15.6M raise - Stock Titan hu, 11 Dec 2025 08
- Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts? - Yahoo Finance Fri, 18 Apr 2025 07
- TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone - PR Newswire Mon, 15 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2323307 | — | — | Stock Award(Grant) at price 0.00 per share. | BIANCO JAMES A | Chief Executive Officer | — | 2024-10-18 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -17.11M | -12.90M | -9.29M | -6.73M |
| TotalUnusualItems | -313.77K | -16.22M | 294.07K | 725.14K |
| TotalUnusualItemsExcludingGoodwill | -313.77K | -16.22M | 294.07K | 725.14K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -21.68M | -29.32M | -9.37M | -7.02M |
| ReconciledDepreciation | 116.71K | 177.38K | 373.09K | 380.69K |
| EBITDA | -17.43M | -29.12M | -8.99M | -6.01M |
| EBIT | -17.54M | -29.30M | -9.37M | -6.39M |
| NetInterestIncome | -3.78M | 70.98K | 57.35K | -629.29K |
| InterestExpense | 4.14M | 18.69K | 0.00 | 629.29K |
| InterestIncome | 361.63K | 89.67K | 57.35K | 0.00 |
| NormalizedIncome | -21.37M | -13.10M | -9.66M | -7.74M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -21.68M | -29.32M | -9.37M | -7.02M |
| TotalExpenses | 17.59M | 13.17M | 9.72M | 7.11M |
| TotalOperatingIncomeAsReported | -17.65M | -29.76M | -9.93M | -7.25M |
| DilutedAverageShares | 18.66M | 11.89M | 12.18M | 12.18M |
| BasicAverageShares | 18.66M | 11.89M | 12.18M | 12.18M |
| DilutedEPS | -1.21 | -2.47 | -0.77 | -0.58 |
| BasicEPS | -1.21 | -2.47 | -0.77 | -0.58 |
| DilutedNIAvailtoComStockholders | -22.65M | -29.32M | -9.37M | -7.02M |
| NetIncomeCommonStockholders | -22.65M | -29.32M | -9.37M | -7.02M |
| OtherunderPreferredStockDividend | 965.18K | 0.00 | ||
| PreferredStockDividends | 2.09K | |||
| NetIncome | -21.68M | -29.32M | -9.37M | -7.02M |
| NetIncomeIncludingNoncontrollingInterests | -21.68M | -29.32M | -9.37M | -7.02M |
| NetIncomeContinuousOperations | -21.68M | -29.32M | -9.37M | -7.02M |
| PretaxIncome | -21.68M | -29.32M | -9.37M | -7.02M |
| OtherIncomeExpense | -313.77K | -16.22M | 294.07K | 725.14K |
| SpecialIncomeCharges | 0.00 | -16.22M | 294.07K | 725.14K |
| OtherSpecialCharges | 16.22M | -294.07K | -404.85K | |
| WriteOff | 0.00 | -320.29K | ||
| GainOnSaleOfSecurity | -313.77K | |||
| NetNonOperatingInterestIncomeExpense | -3.78M | 70.98K | 57.35K | -629.29K |
| InterestExpenseNonOperating | 4.14M | 18.69K | 0.00 | 629.29K |
| InterestIncomeNonOperating | 361.63K | 89.67K | 57.35K | 0.00 |
| OperatingIncome | -17.59M | -13.17M | -9.72M | -7.11M |
| OperatingExpense | 17.59M | 13.17M | 9.72M | 7.11M |
| OtherOperatingExpenses | -57.63K | -42.47K | -214.92K | -142.62K |
| OtherTaxes | 0.00 | -334.44K | 0.00 | |
| ResearchAndDevelopment | 13.34M | 9.40M | 7.93M | 4.88M |
| SellingGeneralAndAdministration | 4.31M | 4.14M | 2.01M | 2.38M |
| GeneralAndAdministrativeExpense | 4.31M | 4.14M | 2.01M | 2.38M |
| OtherGandA | 4.31M | 4.14M | 2.01M | 2.38M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 42.32M | 42.03M | 42.03M | 42.03M |
| ShareIssued | 42.32M | 42.03M | 42.03M | 42.03M |
| TotalDebt | 202.54K | 2.34M | 138.22K | 644.07K |
| TangibleBookValue | 14.32M | -1.58M | 12.30M | -752.52K |
| InvestedCapital | 14.32M | 748.50K | 12.30M | -108.45K |
| WorkingCapital | 14.28M | 562.42K | 11.87M | -1.47M |
| NetTangibleAssets | 14.59M | -1.56M | 12.30M | -747.82K |
| CapitalLeaseObligations | 202.54K | 20.82K | 138.22K | 0.00 |
| CommonStockEquity | 14.32M | -1.58M | 12.30M | -752.52K |
| PreferredStockEquity | 278.53K | 16.91K | 8.06K | 4.70K |
| TotalCapitalization | 14.59M | 765.41K | 12.30M | -747.82K |
| TotalEquityGrossMinorityInterest | 14.59M | -1.56M | 12.30M | -747.82K |
| StockholdersEquity | 14.59M | -1.56M | 12.30M | -747.82K |
| RetainedEarnings | -111.12M | -88.47M | -59.16M | -49.48M |
| AdditionalPaidInCapital | 125.40M | 86.89M | 71.45M | 48.72M |
| CapitalStock | 320.85K | 29.08K | 12.59K | 9.23K |
| CommonStock | 42.32K | 12.17K | 4.53K | 4.53K |
| PreferredStock | 278.53K | 16.91K | 8.06K | 4.70K |
| TotalLiabilitiesNetMinorityInterest | 5.37M | 5.92M | 2.89M | 7.15M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 42.70K | 2.32M | 20.74K | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 42.70K | 2.32M | 20.74K | 0.00 |
| LongTermCapitalLeaseObligation | 42.70K | 0.00 | 20.74K | 0.00 |
| LongTermDebt | 2.32M | |||
| CurrentLiabilities | 5.33M | 3.60M | 2.87M | 7.15M |
| OtherCurrentLiabilities | 137.00K | |||
| CurrentDebtAndCapitalLeaseObligation | 159.84K | 20.82K | 117.48K | 644.07K |
| CurrentCapitalLeaseObligation | 159.84K | 20.82K | 117.48K | 0.00 |
| CurrentDebt | 644.07K | |||
| OtherCurrentBorrowings | 294.07K | |||
| CurrentNotesPayable | 0.00 | 350.00K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.16M | 1.42M | 675.00K | 456.00K |
| PayablesAndAccruedExpenses | 4.01M | 2.02M | 2.08M | 6.05M |
| CurrentAccruedExpenses | 855.70K | 156.40K | 163.68K | 36.18K |
| Payables | 3.15M | 1.87M | 1.92M | 6.01M |
| OtherPayable | 5.60M | |||
| AccountsPayable | 3.15M | 1.87M | 1.92M | 413.79K |
| TotalAssets | 19.97M | 4.36M | 15.20M | 6.40M |
| TotalNonCurrentAssets | 356.30K | 202.99K | 452.32K | 721.04K |
| OtherNonCurrentAssets | 33.77K | 33.77K | 103.90K | |
| NetPPE | 322.53K | 202.99K | 418.55K | 617.14K |
| AccumulatedDepreciation | -2.09M | -1.97M | -1.79M | -1.42M |
| GrossPPE | 2.41M | 2.17M | 2.21M | 2.04M |
| Leases | 544.63K | 544.63K | 544.63K | 544.63K |
| OtherProperties | 199.16K | 20.82K | 138.22K | |
| MachineryFurnitureEquipment | 1.67M | 1.61M | 1.53M | 1.49M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 19.61M | 4.16M | 14.74M | 5.68M |
| OtherCurrentAssets | 316.35K | 159.33K | 491.77K | 135.13K |
| PrepaidAssets | 6.20M | 0.00 | ||
| Receivables | 437.40K | 334.44K | 101.42K | |
| OtherReceivables | 222.70K | |||
| TaxesReceivable | 214.70K | 334.44K | ||
| AccruedInterestReceivable | 101.42K | 1.42K | ||
| NotesReceivable | 100.00K | 100.00K | ||
| CashCashEquivalentsAndShortTermInvestments | 12.66M | 3.67M | 14.25M | 5.55M |
| CashAndCashEquivalents | 12.66M | 3.67M | 14.25M | 5.55M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -14.79M | -12.03M | -7.54M | -6.57M |
| RepurchaseOfCapitalStock | 0.00 | -24.75K | 0.00 | |
| RepaymentOfDebt | 0.00 | -350.00K | 0.00 | |
| IssuanceOfDebt | 28.57M | 2.69M | 0.00 | 294.07K |
| IssuanceOfCapitalStock | 5.00M | 0.00 | 16.60M | 6.75M |
| CapitalExpenditure | -57.91K | -79.22K | -36.28K | -3.28K |
| EndCashPosition | 12.66M | 3.67M | 14.25M | 5.55M |
| BeginningCashPosition | 3.67M | 14.25M | 5.55M | 5.07M |
| ChangesInCash | 8.99M | -10.59M | 8.71M | 477.91K |
| FinancingCashFlow | 29.77M | 2.66M | 16.25M | 7.04M |
| CashFlowFromContinuingFinancingActivities | 29.77M | 2.66M | 16.25M | 7.04M |
| NetOtherFinancingCharges | -5.84M | |||
| ProceedsFromStockOptionExercised | 2.05M | 0.00 | ||
| NetPreferredStockIssuance | 0.00 | 16.60M | 1.15M | |
| PreferredStockIssuance | 0.00 | 16.60M | 1.15M | |
| NetCommonStockIssuance | 5.00M | -24.75K | 0.00 | 5.60M |
| CommonStockPayments | 0.00 | -24.75K | 0.00 | |
| CommonStockIssuance | 5.00M | 0.00 | 0.00 | 5.60M |
| NetIssuancePaymentsOfDebt | 28.57M | 2.69M | -350.00K | 294.07K |
| NetShortTermDebtIssuance | 0.00 | -350.00K | 294.07K | |
| ShortTermDebtPayments | 0.00 | -350.00K | 0.00 | |
| ShortTermDebtIssuance | 0.00 | 294.07K | ||
| NetLongTermDebtIssuance | 28.57M | 2.69M | 0.00 | 294.07K |
| LongTermDebtIssuance | 28.57M | 2.69M | 0.00 | 294.07K |
| InvestingCashFlow | -6.05M | -1.30M | -36.28K | -3.28K |
| CashFlowFromContinuingInvestingActivities | -6.05M | -1.30M | -36.28K | -3.28K |
| NetBusinessPurchaseAndSale | -5.99M | -1.22M | 0.00 | |
| PurchaseOfBusiness | -5.99M | -1.22M | 0.00 | |
| NetPPEPurchaseAndSale | -57.91K | -79.22K | -36.28K | -3.28K |
| PurchaseOfPPE | -57.91K | -79.22K | -36.28K | -3.28K |
| OperatingCashFlow | -14.73M | -11.95M | -7.51M | -6.56M |
| CashFlowFromContinuingOperatingActivities | -14.73M | -11.95M | -7.51M | -6.56M |
| ChangeInWorkingCapital | 3.29M | 486.92K | 1.56M | -486.20K |
| ChangeInOtherWorkingCapital | -24.40K | |||
| ChangeInOtherCurrentLiabilities | 70.13K | 228.00 | ||
| ChangeInOtherCurrentAssets | -358.32K | 149.18K | -286.51K | 8.54K |
| ChangeInPayablesAndAccruedExpense | 3.64M | 337.75K | 1.85M | -470.34K |
| OtherNonCashItems | 1.28M | 5.12K | 629.29K | |
| StockBasedCompensation | 1.96M | 478.89K | 218.28K | 654.53K |
| AssetImpairmentCharge | 0.00 | 16.22M | 0.00 | -320.29K |
| DepreciationAmortizationDepletion | 116.71K | 177.38K | 373.09K | 380.69K |
| DepreciationAndAmortization | 116.71K | 177.38K | 373.09K | 380.69K |
| OperatingGainsLosses | 313.77K | -294.07K | -404.85K | |
| GainLossOnInvestmentSecurities | 313.77K | |||
| NetIncomeFromContinuingOperations | -21.68M | -29.32M | -9.37M | -7.02M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for HURA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|